← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV15행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 1
PD-1 Knockout T Cells (PD-1 Knockout T Cells)
Bioray Laboratories·PD-1
16 trials
Overview
Program
PD-1 Knockout T Cells
Overview
Company
Bioray Laboratories
Overview
Modality
CGT
Overview
Target
PD-1
Overview
Indication
Metastatic Renal Cell Carcinoma
Overview
Phase
PHASE_1
Overview
Status
DISCONTINUED
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Toxicology
Major finding
In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications.. Since its mechanism discovery in 2012 and the first application for mammalian genome editing in 2013, CRISPR-Cas9 has revolutionized the genome engineering field and created countless opportunities in both basic science and translational medicine. The first clinical trial of CRISPR therapeutics was initiated i…
Toxicology
CRS
Grade 1
Clinical
Safety signal
In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications.. Since its mechanism discovery in 2012 and the first application for mammalian genome editing in 2013, CRISPR-Cas9 has revolutionized the genome engineering field and created countless opportunities in both basic science and translational medicine. The first clinical trial of CRISPR therapeutics was initiated i…
Clinical
Program phase
PHASE_1